These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 27748158)

  • 41. Seroprevalence and diagnosis of HIV, HBV, HCV and syphilis infections among blood donors.
    Tafesse TB; Gebru AA; Gobalee S; Belay GD; Belew MT; Ataro D; Ebrahim BA; Shebeshi GM; Yimam Y
    Hum Antibodies; 2017; 25(1-2):39-55. PubMed ID: 28009328
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Relative safety of first-time volunteer and replacement donors in West Africa.
    Allain JP; Sarkodie F; Asenso-Mensah K; Owusu-Ofori S
    Transfusion; 2010 Feb; 50(2):340-3. PubMed ID: 19843284
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Does Pay-For-Performance Program Increase Providers Adherence to Guidelines for Managing Hepatitis B and Hepatitis C Virus Infection in Taiwan?
    Chen HJ; Huang N; Chen LS; Chou YJ; Li CP; Wu CY; Chang YC
    PLoS One; 2016; 11(8):e0161002. PubMed ID: 27517172
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Fighting viral hepatitis B and C in Africa. Focus on Benin].
    Kodjoh N
    Med Sante Trop; 2015; 25(2):141-4. PubMed ID: 26039152
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-benefit evaluation of a preventive intervention on the biological risk in health: the accidental puncture during the administration of insulin in the University Hospital "Federico II" of Naples.
    Montella E; Schiavone D; Apicella L; Di Silverio P; Gaudiosi M; Ambrosone E; Moscaritolo E; Triassi M
    Ann Ig; 2014; 26(3):272-8. PubMed ID: 24998218
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevalence of hepatitis B and C in Egypt and Africa.
    Attia MA
    Antivir Ther; 1998; 3(Suppl 3):1-9. PubMed ID: 10726051
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Transfusion safety].
    Aprili G
    Haematologica; 1991 Jun; 76 Suppl 3():385-94. PubMed ID: 1752537
    [No Abstract]   [Full Text] [Related]  

  • 48. Prevention of viral hepatitis (B and C) reassessed.
    Van Herck K; Vorsters A; Van Damme P
    Best Pract Res Clin Gastroenterol; 2008; 22(6):1009-29. PubMed ID: 19187864
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Transmission of hepatitis B, hepatitis C and human immunodeficiency viruses through unsafe injections in the developing world: model-based regional estimates.
    Kane A; Lloyd J; Zaffran M; Simonsen L; Kane M
    Bull World Health Organ; 1999; 77(10):801-7. PubMed ID: 10593027
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bloodborne infections: should they be disclosed? Is differential treatment necessary?
    Kukka C
    J Sch Nurs; 2004 Dec; 20(6):324-30. PubMed ID: 15560729
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Minimal transmission of HIV despite persistently high transmission of hepatitis C virus in a Swedish needle exchange program.
    Blomé MA; Björkman P; Flamholc L; Jacobsson H; Molnegren V; Widell A
    J Viral Hepat; 2011 Dec; 18(12):831-9. PubMed ID: 21114587
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The BASHH HIV Special Interest Group (SIG).
    Waters L; Edwards S
    Sex Transm Infect; 2015 Feb; 91(1):6. PubMed ID: 25609464
    [No Abstract]   [Full Text] [Related]  

  • 53. Management of health care workers following occupational exposure to hepatitis B, hepatitis C, and human immunodeficiency virus.
    Sin WW; Lin AW; Chan KC; Wong KH
    Hong Kong Med J; 2016 Oct; 22(5):472-7. PubMed ID: 27562987
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Federal and State Action Needed to End the Infectious Complications of Illicit Drug Use in the United States: IDSA and HIVMA's Advocacy Agenda.
    Springer SA; Barocas JA; Wurcel A; Nijhawan A; Thakarar K; Lynfield R; Hurley H; Snowden J; Thornton A; Del Rio C
    J Infect Dis; 2020 Sep; 222(Suppl 5):S230-S238. PubMed ID: 32877568
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Estimating the cost-effectiveness of needle-syringe programs in Australia.
    Kwon JA; Anderson J; Kerr CC; Thein HH; Zhang L; Iversen J; Dore GJ; Kaldor JM; Law MG; Maher L; Wilson DP
    AIDS; 2012 Nov; 26(17):2201-10. PubMed ID: 22914579
    [TBL] [Abstract][Full Text] [Related]  

  • 56. National surveillance of dialysis associated diseases in the United States, 1992.
    Tokars JI; Alter MJ; Favero MS; Moyer LA; Miller E; Bland LA
    ASAIO J; 1994; 40(4):1020-31. PubMed ID: 7858322
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Letter in response to the new SHEA guideline for healthcare workers with hepatitis B virus, hepatitis C virus, and/or human immunodeficiency virus.
    Saag MS; Squires KE; Aberg JA; Bardeguez A
    Infect Control Hosp Epidemiol; 2010 Oct; 31(10):1092-3; author reply 1093-5. PubMed ID: 20812818
    [No Abstract]   [Full Text] [Related]  

  • 58. The global burden of hepatitis C.
    Lavanchy D
    Liver Int; 2009 Jan; 29 Suppl 1():74-81. PubMed ID: 19207969
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The increasing impact of human immunodeficiency virus infections, sexually transmitted diseases, and viral hepatitis in Durham County, North Carolina: a call for coordinated and integrated services.
    Kolman M; DeCoster M; Proeschold-Bell RJ; Hunter GA; Bartlett J; Seña AC
    N C Med J; 2011; 72(6):439-46. PubMed ID: 22523850
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Knowledge about hepatitis B and C viruses and HIV among blood donors in Casablanca].
    Boutayeb H; Aamoum A; Benchemsi N
    East Mediterr Health J; 2006 Sep; 12(5):538-47. PubMed ID: 17333791
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.